Belpointe Asset Management’s Vir Biotechnology VIR Stock Holding History

Belpointe Asset Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-177	Closed	-$4.12K	–	3291
2023 Q1	$4.12K	Buy	177 +78	+79%	+$2K	﹤0.01%	3087
2022 Q4	$2.51K	Buy	+99	New	+$2.43K	﹤0.01%	3182
2021 Q4	–	Sell	-25,099	Closed	-$1.09M	–	1258
2021 Q3	$1.09M	Buy	+25,099	New	+$1.09M	0.07%	287
2021 Q1	–	Sell	-20,559	Closed	-$551K	–	1078
2020 Q4	$551K	Buy	+20,559	New	+$668K	0.05%	377

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Belpointe Asset Management's VIR Position: Q2 2023 in Review

Belpointe Asset Management sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 177 shares — an estimated $4.12K sold.

Belpointe Asset Management first reported a position in VIR in Q4 2020 and held it in 4 quarters. The position peaked at $1.09M in Q3 2021. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

Belpointe Asset Management reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 177 Vir Biotechnology shares in Q2 2023, an estimated $4.12K.
Belpointe Asset Management first reported a position in Vir Biotechnology in Q4 2020 and held it in 4 quarters.
Belpointe Asset Management's Vir Biotechnology position peaked at $1.09M in Q3 2021.
226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.